Skip to main content

Table 1 Demographic data, clinical parameters at presentation, treatments given, and outcome data for all patients within the vasculitis service and also categorised by ANCA subtype

From: Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service

Characteristic

PR3+ (n = 51)

MPO+ (n = 46)

ANCA-a (n = 7)

Overall (n = 104)

Age

58 ± 15

64 ± 19

61 ± 4

61 ± 16

Male / Female

26 /25

21 / 25

5 / 2

52 / 52

Renal involvement (%)

45 (88)

44 (96)

4 (57)

93 (89)

At presentation

    

Creatinine (ÎĽmol/l)

225 ± 225

330 ± 239

234 ± 216

272 ± 235

CRP (mg/l)

97 ± 86

73 ± 73

38 ± 40

82 ± 79

Haemoglobin (g/l)

107 ± 23

98 ± 18

114 ± 28

103 ± 22

Dialysis-requiring

9

11

1

21

Induction period (~3 months)

    

Number (%) of patients receiving

    

Glucocorticoids

51 (100)

46 (100)

7 (100)

104 (100)

CYC

35 (69)

30 (65)

3 (43)

68 (65)

MMF

9 (18)

18 (39)

2 (29)

29 (28)

Rituximab

6 (12)

15 (33)

1 (14)

22 (21)

Plasma exchange

25 (49)

30 (65)

3 (43)

58 (56)

Cumulative glucocorticoid dose (g)

2.3 ± 0.3

2.4 ± 0.3

2.2 ± 0.0

2.3 ± 0.3

Cumulative CYC dose (g)

6.5 ± 3.2

6.4 ± 3.9

5.3 ± 1.0

6.3 ± 3.4

Remission

    

Number entering remission (%)

50 (98)

44 (96)

7 (100)

101b (97)

Time to remission (days)

108 ± 184

82 ± 29

124 ± 149

98 ± 136

At 12 months

    

Creatinine (ÎĽmol/l)

124 ± 57

215 ± 193

120 ± 68

158 ± 132

Dialysis-requiring

1

4

0

5

Relapses & mortality

    

Number of patients with disease relapses (%)

15 (29)

4 (9)

1 (14)

20 (19)

Mean time to first relapse (days)

880 ± 692

1073 ± 877

635 ± 760

953 ± 786

Median time to first relapse (days & IQR)

754 (823)

857 (1252)

223 (1078)

795 (1102)

Number of patients died (%)

5 (10)

4 (9)

0 (0)

9 (9)

  1. ANCA anti-neutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, EGPA eosinophilic granulomatosis with polyangiitis, ENT ear, nose & throat, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase-3. Data are shown as number of patients (%), mean ± standard deviation or median and IQR. aThe 7 patients that were ANCA- had evidence of a pauci-immune necrotising glomerulonephritis on renal biopsy. b3 patients did not enter remission as they died during before this